معرفی
Professor Roger Chung is a leading academic in neurobiology and neurochemistry at Macquarie University, serving as Deputy Dean (Research & Innovation) in the Faculty of Medicine, Health & Human Sciences, and Pro Vice-Chancellor, Academic Health Strategy. He leads the Neurochemistry & Molecular Therapeutics Group and the Macquarie University Centre for Motor Neuron Disease Research. His research focuses on neurodegenerative diseases, particularly ALS/MND, integrating molecular, cellular, and proteomic approaches to understand disease mechanisms and develop therapies. Key projects include investigating protein aggregates in MND, AAV gene therapies targeting cyclin F, and founding Celosia Therapeutics for translational research.
Chung completed his PhD in molecular biology (2003) and led research teams at the University of Tasmania (2004–2013) before joining Macquarie. He co-led the establishment of the Centre for Motor Neuron Disease Research (2013), which employs multidisciplinary methods including synthetic biology, animal models, and patient trials. Collaborators include Dr. Albert Lee and A/Professor Marco Morsch. His work has identified CCNF mutations and TDP-43 ubiquitylation as critical pathways in ALS/FTD pathogenesis.
He has received the Jim Piper Award for Excellence in Research Leadership (2019) and holds patents related to gene therapies. Current projects include developing gene expression control mechanisms for ALS therapies and exploring TDP-43’s role in cryptic exons. His research spans proteomics, synthetic biology, and clinical trials, with over 180 publications in high-impact journals like Nature Communications and Neurobiology of Disease.
